Pluri Inc

PLUR

Company Profile

  • Business description

    Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.

  • Contact

    MATAM Advanced Technology Park
    Building No. 5
    Haifa3508409
    ISR

    T: +972 747108600

    E: [email protected]

    https://www.pluri-biotech.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    142

Stocks News & Analysis

stocks

Strong guidance from undervalued ASX share

Shares surged after the announcement of first half fiscal 2026 guidance.
stocks

TSMC earnings: Refining guidance and expansion plans amid strong AI demand

We maintain our fair value estimate for TSMC stock.
stocks

Unconventional wisdom: A top performing ‘AI share’ accidently ended up in my portfolio

Trying to make sense of a share caught up in irrational exuberance.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,155.9020.200.22%
CAC 408,262.7011.87-0.14%
DAX 4024,154.4787.770.36%
Dow JONES (US)48,578.72115.000.24%
FTSE 10010,589.9930.410.29%
HKSE26,046.70347.56-1.32%
NASDAQ24,102.7086.690.36%
Nikkei 22558,994.41523.93-0.88%
NZX 50 Index12,962.32103.74-0.79%
S&P 5007,041.2818.330.26%
S&P/ASX 2008,935.9025.800.29%
SSE Composite Index4,043.4512.10-0.30%

Market Movers